novo nordisk's semaglutide failed to slow alzheimer's disease progression reports 2 trial failures for GLP-1 in 🚨Ozempic & dementia discovery #ozempic

ZP CON BS 20DEC2024 Zepbound and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates

Related Blog Posts:

A study published in the Journal of Pharmacy Technology compared oral and injectable semaglutide and found no significant differences in weight loss or blood sugar control after 26 weeks

In the present study, we speculate that the primary pathway through which GS supplementation improves dyslipidemia in hyperglycemic rats is mainly through enhanced hepatic signaling of insulin depicted by the increased transcriptional activity of Irs1 and Irs2 genes (Figure 7A)

You can read the full article at Research studies in anatomy, physiology, pharmacology, and behavior have provided evidence of a connection between the neurotensin (NT) and dopamine (DA) systems

Management: Generally safe